VeriMomborago officinalis leaf extract est-il sûr pendant la grossesse ?
No EU Cosmetic Regulation ban (Annex II) or Annex III restriction or harmonised CLP H360/H361 was identified for Borago officinalis leaf extract. However, the plant family (Boraginaceae) is known to produce pyrrolizidine alkaloids (PAs) which have demonstrated toxic and genotoxic mechanisms in animals and humans; this represents a class-based concern (h=1) with a demonstrated mechanism (m=2). Topical cosmetic use of a leaf extract is likely low but measurable exposure (e=1). Sources: EU INCI listing for Borago Officinalis Extract, PubMed reviews on borage/PAs, and EWG ingredient summary.
Alternatives sûres à borago officinalis leaf extract pendant la grossesse | VeriMom
Related ingredients
Frequently asked questions
- borago officinalis leaf extract est-il sûr pendant la grossesse ?
- No EU Cosmetic Regulation ban (Annex II) or Annex III restriction or harmonised CLP H360/H361 was identified for Borago officinalis leaf extract. However, the plant family (Boraginaceae) is known to produce pyrrolizidine alkaloids (PAs) which have demonstrated toxic and genotoxic mechanisms in animals and humans; this represents a class-based concern (h=1) with a demonstrated mechanism (m=2). Topical cosmetic use of a leaf extract is likely low but measurable exposure (e=1). Sources: EU INCI listing for Borago Officinalis Extract, PubMed reviews on borage/PAs, and EWG ingredient summary.
- borago officinalis leaf extract est-il sûr pendant l'allaitement ?
- Same rationale as pregnancy: no regulatory ban or harmonised reproductive classification found, but PA-related hepatotoxic/genotoxic concerns for Borago officinalis warrant a class-level caution (h=1). Mechanistic evidence for PA toxicity exists (m=2). Topical use implies low but measurable exposure (e=1); systemic transfer into breastmilk after dermal cosmetic use has not been demonstrated.
- borago officinalis leaf extract est-il sûr pour la peau de bébé ?
- Hazard (h=1) remains driven by the plant’s PA class concern rather than any infant-specific reproductive data. Mechanistic concern from PAs (m=2) remains. Exposure is increased for babies (elevated by +1 to e=2) because infant skin has higher surface-area-to-weight and an immature barrier, so topical absorption (if any) is proportionally higher even though absolute systemic exposure from a cosmetic extract is expected to be low.
- Comment VeriMom évalue-t-il borago officinalis leaf extract ?
- VeriMom évalue borago officinalis leaf extract à 60/100 (risque moyen) sur la base du statut EU CosIng, des classifications ECHA et des études PubMed.
- Quelles sont les alternatives sûres à borago officinalis leaf extract pendant la grossesse ?
- Consultez notre liste d'alternatives sûres à borago officinalis leaf extract basée sur une fonction similaire et une classification sans risques connus.
Vérifiez chaque étiquette en 2 secondes
Obtenez VeriMom gratuitement — scannez n'importe quel produit et voyez le score de sécurité grossesse instantanément.
Avis Médical
Ces informations sont fournies à titre éducatif uniquement et ne constituent pas un avis médical. Les scores de sécurité sont basés sur des données accessibles au public et peuvent ne pas refléter tous les risques. Consultez toujours votre professionnel de santé avant d'utiliser tout produit pendant la grossesse ou l'allaitement.